Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

New Insights into Ejaculatory Frequency and Prostate Cancer Risk: Association, Causation, or What Do We Have to Lose?

Dall'Era MA, De Vere White RW.

Eur Urol. 2018 Nov;74(5):549-550. doi: 10.1016/j.eururo.2018.08.014. Epub 2018 Sep 1. No abstract available.

PMID:
30177292
2.

COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin.

Wang F, Zhang H, Ma AH, Yu W, Zimmermann M, Yang J, Hwang SH, Zhu D, Lin TY, Malfatti M, Turteltaub KW, Henderson PT, Airhart S, Hammock BD, Yuan J, de Vere White RW, Pan CX.

Mol Cancer Ther. 2018 Feb;17(2):474-483. doi: 10.1158/1535-7163.MCT-16-0818. Epub 2017 Dec 28.

3.

Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.

Wang M, Yao LC, Cheng M, Cai D, Martinek J, Pan CX, Shi W, Ma AH, De Vere White RW, Airhart S, Liu ET, Banchereau J, Brehm MA, Greiner DL, Shultz LD, Palucka K, Keck JG.

FASEB J. 2018 Mar;32(3):1537-1549. doi: 10.1096/fj.201700740R. Epub 2018 Jan 3.

4.

Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells.

Gheibi P, Zeng S, Son KJ, Vu T, Ma AH, Dall'Era MA, Yap SA, de Vere White RW, Pan CX, Revzin A.

Sci Rep. 2017 Sep 25;7(1):12277. doi: 10.1038/s41598-017-12543-9.

5.

Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.

Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, Ghosh PM, Gill P, Airhart S, Bult C, Gandara DR, Liu E, de Vere White RW.

PLoS One. 2015 Aug 13;10(8):e0134346. doi: 10.1371/journal.pone.0134346. eCollection 2015.

6.

Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform.

Gandara DR, Mack PC, Bult C, Li T, Lara PN Jr, Riess JW, Astrow SH, Gandour-Edwards R, Cooke DT, Yoneda KY, Moore EH, Pan CX, Burich RA, David EA, Keck JG, Airhart S, Goodwin N, de Vere White RW, Liu ET.

Clin Lung Cancer. 2015 May;16(3):165-72. doi: 10.1016/j.cllc.2015.03.001. Epub 2015 Mar 18.

7.

Human ESC self-renewal promoting microRNAs induce epithelial-mesenchymal transition in hepatocytes by controlling the PTEN and TGFβ tumor suppressor signaling pathways.

Jung CJ, Iyengar S, Blahnik KR, Jiang JX, Tahimic C, Torok NJ, de vere White RW, Farnham PJ, Zern M.

Mol Cancer Res. 2012 Jul;10(7):979-91. doi: 10.1158/1541-7786.MCR-11-0421. Epub 2012 May 23.

8.

Dual blockade of PKA and NF-κB inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis.

Vinall RL, Mahaffey CM, Davis RR, Luo Z, Gandour-Edwards R, Ghosh PM, Tepper CG, de Vere White RW.

Horm Cancer. 2011 Aug;2(4):224-38. doi: 10.1007/s12672-011-0076-4.

9.

A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance.

Henderson PT, Li T, He M, Zhang H, Malfatti M, Gandara D, Grimminger PP, Danenberg KD, Beckett L, de Vere White RW, Turteltaub KW, Pan CX.

Int J Cancer. 2011 Sep 15;129(6):1425-34. doi: 10.1002/ijc.25814. Epub 2011 Mar 4.

10.

Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710).

Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, de Vere White RW, Vogelzang NJ, Trump DL, Natale RB, Tangen CM, Crawford ED, Thompson IM.

BJU Int. 2011 Sep;108(5):693-9. doi: 10.1111/j.1464-410X.2010.09900.x. Epub 2010 Nov 24.

11.

Nuclear versus cytoplasmic localization of filamin A in prostate cancer: immunohistochemical correlation with metastases.

Bedolla RG, Wang Y, Asuncion A, Chamie K, Siddiqui S, Mudryj MM, Prihoda TJ, Siddiqui J, Chinnaiyan AM, Mehra R, de Vere White RW, Ghosh PM.

Clin Cancer Res. 2009 Feb 1;15(3):788-96. doi: 10.1158/1078-0432.CCR-08-1402.

12.

Detecting glycan cancer biomarkers in serum samples using MALDI FT-ICR mass spectrometry data.

Barkauskas DA, An HJ, Kronewitter SR, de Leoz ML, Chew HK, de Vere White RW, Leiserowitz GS, Miyamoto S, Lebrilla CB, Rocke DM.

Bioinformatics. 2009 Jan 15;25(2):251-7. doi: 10.1093/bioinformatics/btn610. Epub 2008 Dec 9.

13.

Characterization of oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations.

Hah SS, Sumbad RA, de Vere White RW, Turteltaub KW, Henderson PT.

Chem Res Toxicol. 2007 Dec;20(12):1745-51. Epub 2007 Nov 15.

PMID:
18001055
14.

Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis.

Vinall RL, Hwa K, Ghosh P, Pan CX, Lara PN Jr, de Vere White RW.

Clin Cancer Res. 2007 Oct 15;13(20):6204-16.

15.

Finasteride for chemoprevention of prostate cancer: why has it not been embraced?

de Vere White RW.

J Clin Oncol. 2007 Jul 20;25(21):2999-3000. No abstract available.

PMID:
17634478
16.

GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.

Tepper CG, Vinall RL, Wee CB, Xue L, Shi XB, Burich R, Mack PC, de Vere White RW.

Prostate. 2007 Apr 1;67(5):521-35.

PMID:
17252539
17.

Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study.

Grossman HB, Tangen CM, Cordon-Cardo C, Cote R, Waldman FM, De Vere White RW, Karnad AB, Glode M, Crawford ED.

Oncol Rep. 2006 Oct;16(4):807-10.

PMID:
16969498
18.

Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules.

Burke PA, Gregg JP, Bakhtiar B, Beckett LA, Denardo GL, Albrecht H, De Vere White RW, De Nardo SJ.

Int J Oncol. 2006 Jul;29(1):49-55.

PMID:
16773184
19.

Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry.

Hah SS, Stivers KM, de Vere White RW, Henderson PT.

Chem Res Toxicol. 2006 May;19(5):622-6.

PMID:
16696564
20.

The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7.

Vinall RL, Tepper CG, Shi XB, Xue LA, Gandour-Edwards R, de Vere White RW.

Oncogene. 2006 Mar 30;25(14):2082-93.

PMID:
16434975
21.

Interleukin-17 receptor-like gene is a novel antiapoptotic gene highly expressed in androgen-independent prostate cancer.

You Z, Shi XB, DuRaine G, Haudenschild D, Tepper CG, Lo SH, Gandour-Edwards R, de Vere White RW, Reddi AH.

Cancer Res. 2006 Jan 1;66(1):175-83.

22.

The androgen receptor and mechanisms for androgen independence in prostate cancer.

Javidan J, Deitch AD, Shi XB, de Vere White RW.

Cancer Invest. 2005;23(6):520-8. Review. No abstract available.

PMID:
16203660
23.

Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status.

Wetherill YB, Fisher NL, Staubach A, Danielsen M, de Vere White RW, Knudsen KE.

Cancer Res. 2005 Jan 1;65(1):54-65.

24.
25.
26.

Functional analysis of 44 mutant androgen receptors from human prostate cancer.

Shi XB, Ma AH, Xia L, Kung HJ, de Vere White RW.

Cancer Res. 2002 Mar 1;62(5):1496-502.

27.

Predicting prognosis in patients with superficial bladder cancer.

de Vere White RW, Stapp E.

Oncology (Williston Park). 1998 Dec;12(12):1717-23; discussion 1724-6. Review.

28.

CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.

Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG.

Cancer Res. 1996 Jul 1;56(13):3042-6.

29.

Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues.

Wertz IE, Deitch AD, Gumerlock PH, Gandour-Edwards R, Chi SG, de Vere White RW.

Hum Pathol. 1996 Jun;27(6):573-80.

PMID:
8666367
30.

False DNA aneuploidy in canine and human neoplasms.

Deitch AD, de Vere White RW, Madewell BR.

Anticancer Res. 1993 Nov-Dec;13(6A):2117-8.

PMID:
8297122
31.

Consensus review of the clinical utility of DNA cytometry in bladder cancer. Report of the DNA Cytometry Consensus Conference.

Wheeless LL, Badalament RA, de Vere White RW, Fradet Y, Tribukait B.

Cytometry. 1993;14(5):478-81. Review. No abstract available.

32.

Comparison of flow cytometry to routine testicular biopsy in male infertility.

Hellstrom WJ, Tesluk H, Deitch AD, de Vere White RW.

Urology. 1990 Apr;35(4):321-6.

PMID:
2321325
33.

Measurement variability in DNA flow cytometry of replicate samples.

Wheeless LL, Coon JS, Cox C, Deitch AD, de Vere White RW, Koss LG, Melamed MR, O'Connell MJ, Reeder JE, Weinstein RS, et al.

Cytometry. 1989 Nov;10(6):731-8.

34.

Deoxyribonucleic acid flow cytometry of benign prostatic disease.

Deitch AD, Strand MA, de Vere White RW.

J Urol. 1989 Sep;142(3):759-62.

PMID:
2769856
35.

RAS enzyme-linked immunoblot assay discriminates p21 species: a technique to dissect gene family expression.

Gumerlock PH, Meyers FJ, Kokoris SP, Wong G, McCormick FP, de Vere White RW.

Anal Biochem. 1989 Jul;180(1):158-68.

PMID:
2683857
36.

Check samples for laboratory self-assessment in DNA flow cytometry. The National Cancer Institute's Flow Cytometry Network experience.

Coon JS, Deitch AD, de Vere White RW, Koss LG, Melamed MR, Reeder JE, Weinstein RS, Wersto RP, Wheeless LL.

Cancer. 1989 Apr 15;63(8):1592-9.

PMID:
2924266
37.

Interinstitutional variability in DNA flow cytometric analysis of tumors. The National Cancer Institute's Flow Cytometry Network Experience.

Coon JS, Deitch AD, de Vere White RW, Koss LG, Melamed MR, Reeder JE, Weinstein RS, Wersto RP, Wheeless LL.

Cancer. 1988 Jan 1;61(1):126-30.

PMID:
3334939

Supplemental Content

Loading ...
Support Center